pegunigalsidase alfa
Protein / enzyme therapeutic
Evidence outlook
Approved: Fabry Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03566017 NCT03566017 · Fabry Disease This was a genuine open-label extension of studies PB-102-F03, PB-102-F20, and PB-102-F30, with 97 participants and 81 completing the extension, but it was single-arm and unblinded with no comparator. Its primary focus was treatment-related adverse events rather than a randomized clinical efficacy comparison, so the findings provide useful long-term safety and descriptive follow-up evidence but cannot establish comparative treatment benefit. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-related Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT03566017 | 3 | Number of Participants With Treatment-related Adverse Events (From first ever infusion of pegunigalsidase alfa, which could have been in the parent study (PB-102-F01/F20/F30) or this extension study, CLI-06657AA1-04, until 90 days after the final dose visit for each participant. Mean individual exposure: 5.5 years) 2025-01-21 | Number of Participants With Treatment-related Adverse Events (From first ever infusion of pegunigalsidase alfa, which could have been in the parent study (PB-102-F01/F20/F30) or this extension study, CLI-06657AA1-04, until 90 days after the final dose visit for each participant. Mean individual exposure: 5.5 years): Experimental Open Label — At least one related TEAE: 46 Participants; Infusion related reaction: 8 Participants; Nausea: 6 Participants; Pruritus: 5 Participants; Headache: 4 Participants; Abdominal pain: 3 Participants; Chills: 3 Participants; Dizziness: 3 Participants; Fatigue: 3 Participants; Vomiting: 3 Participants; Body temperature increased: 2 Participants; Chest discomfort: 2 Participants; Diarhoea: 2 Participants; Hypersensitivity: 2 Participants; Infusion site extravasation: 2 Participants; Oedema peripheral: 2 Participants; Paraesthesia: 2 Participants; Peripheral swelling: 2 Participants; Sneezing: 2 Participants; Supraventricular extrasystoles: 2 Participants; Weight increased: 2 Participants | Weak signal | link ↗ |
View 3 more trials
NCT03614234 NCT03614234 · Fabry Disease Registry: NCT03614234 | 3 | Evaluation of treatment-related adverse events (Throughout the study, 364 weeks) 2026-04-13 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT01678898 NCT01678898 · Fabry Disease The study was an open-label, non-randomized dose-ranging study without a placebo or active comparator and enrolled only 18 participants. Its primary endpoint was safety rather than a comparative clinical efficacy outcome, so there was no formal efficacy comparison to meet or miss. Registry: NCT01678898 | 1/2 | Adverse Events (12 months) 2016-03-06 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
BALANCE NCT02795676 · Fabry Disease This was a randomized, double-blind trial of 78 patients against the established enzyme therapy agalsidase beta, and pegunigalsidase alfa was shown non-inferior on the yearly rate of kidney function decline over 2 years. The trial enrolled the 78 patients its protocol planned. Registry: NCT02795676 | 3 | Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months) 2021-10 | Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other Alpha-galactosidase A (GLA / α-Gal A) drugs
Agalsidase beta, Migalastat, isaralgagene civaparvovec. Compare all 4 Alpha-galactosidase A (GLA / α-Gal A) drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Fabry Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pegunigalsidase Alfa: this drug | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) | |
| Agalsidase Beta (Fabrazyme) | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | Weak signal | NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase. | |
| Migalastat (Galafold) | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | Partial signal | NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed | |
| Isaralgagene Civaparvovec | Phase 1/2 | Gene therapy / editing | Alpha-galactosidase A (GLA / α-Gal A) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow pegunigalsidase alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.